- $11.56bn
- $14.26bn
- $5.81bn
- 93
- 51
- 82
- 89
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 22.75 | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | -17.67% | ||
Dividend Yield (f) | 1.69% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.2 | ||
Price to Tang. Book | 9.58 | ||
Price to Free Cashflow | 19.08 | ||
Price to Sales | 1.99 | ||
EV to EBITDA | 11.77 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 7.45% | ||
Return on Equity | 7.86% | ||
Operating Margin | 11.31% |
Financial Summary
Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 4,560 | 5,212 | 5,215 | 5,549 | 5,810 | 6,078.39 | 6,400.06 | 2.49% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | -30.9 | +2.88 | -28.4 | +64.96 | +12.51 | -28.17 | +13.73 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. Its segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that help surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
Directors
- Roberto Quarta NEC (71)
- Roland Diggelmann CEO (54)
- Anne-Francoise Nesmes CFO (49)
- Brad Cannon CEX (53)
- Peter Coenen CEX (59)
- Myra Eskes CEX (49)
- Simon Fraser CEX (53)
- Mark Gladwell CEX (45)
- Skip Kiil CEX (46)
- Vasant Padmanabhan CEX (54)
- Elga Lohler CHO (53)
- Catheryn O'Rourke CCO (48)
- Phil Cowdy OTH (53)
- Melissa Guerdan OTH (46)
- Susan Swabey SEC (59)
- Jo Hallas NED
- Erik Engstrom NID (57)
- Robin Freestone NID (62)
- John Ma NID (58)
- Katarzyna Mazur-Hofsaess NID (57)
- Rick Medlock NID (61)
- Marc Owen NID (62)
- Angie Risley NID (62)
- Bob White NID (58)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 17th, 1937
- Public Since
- August 13th, 1951
- No. of Shareholders
- 10,973
- No. of Employees
- 17,349
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
New York Stock Exchange
- Shares in Issue
- 875,927,802

- Address
- Building 5, Croxley Park, Hatters Lane, WATFORD, WD18 8YE
- Web
- https://www.smith-nephew.com/
- Phone
- +44 2074017646
- Auditors
- Deloitte LLP
Latest News for SNN
Upcoming Events for SNN
Similar to SNN
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
Avanos Medical
New York Stock Exchange
FAQ
As of Today at 23:19 UTC, shares in Smith & Nephew are trading at $26.64. This share price information is delayed by 15 minutes.
Shares in Smith & Nephew last closed at $26.64 and the price had moved by +11.56% over the past 365 days. In terms of relative price strength the Smith & Nephew share price has outperformed the S&P500 Index by +2.97% over the past year.
The overall consensus recommendation for Smith & Nephew is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Smith & Nephew dividend yield is 1.73% based on the trailing twelve month period.
Last year, Smith & Nephew paid a total dividend of $0.46, and it currently has a trailing dividend yield of 1.73%.Looking ahead, the next dividend pay date is 2025-05-28.
We do not have data on when Smith & Nephew is to next pay dividends. The historic dividend yield on Smith & Nephew shares is currently 1.73%.
To buy shares in Smith & Nephew you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $26.64, shares in Smith & Nephew had a market capitalisation of $11.56bn.
Here are the trading details for Smith & Nephew:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: SNN
Based on an overall assessment of its quality, value and momentum Smith & Nephew is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Smith & Nephew is $30.28. That is 13.66% above the last closing price of $26.64.
Analysts covering Smith & Nephew currently have a consensus Earnings Per Share (EPS) forecast of $1.12 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Smith & Nephew. Over the past six months, its share price has underperformed the S&P500 Index by -1.03%.
As of the last closing price of $26.64, shares in Smith & Nephew were trading -3.42% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Smith & Nephew PE ratio based on its reported earnings over the past 12 months is 22.75. The shares last closed at $26.64.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Smith & Nephew's management team is headed by:
- Roberto Quarta - NEC
- Roland Diggelmann - CEO
- Anne-Francoise Nesmes - CFO
- Brad Cannon - CEX
- Peter Coenen - CEX
- Myra Eskes - CEX
- Simon Fraser - CEX
- Mark Gladwell - CEX
- Skip Kiil - CEX
- Vasant Padmanabhan - CEX
- Elga Lohler - CHO
- Catheryn O'Rourke - CCO
- Phil Cowdy - OTH
- Melissa Guerdan - OTH
- Susan Swabey - SEC
- Jo Hallas - NED
- Erik Engstrom - NID
- Robin Freestone - NID
- John Ma - NID
- Katarzyna Mazur-Hofsaess - NID
- Rick Medlock - NID
- Marc Owen - NID
- Angie Risley - NID
- Bob White - NID